Diurnal Group - US FDA agrees an SPA for Chronocort

Basilea - Lisavanbulin shows further promise

Diurnal receives UK marketing approval for Efmody

Five reasons to invest in healthcare and biotechnology

Diurnal Group - Er-Kim distribution agreement

Basilea - Lisavanbulin ASCO presentation

Diurnal Group - Globalisation of the adrenal franchise

Diurnal significantly increases exposure to the Chinese market

Basilea - The bacteraemia opportunity

Diurnal Group - Efmody (Chronocort) recommended for approval in EU

Basilea - Amgen to acquire Five Prime Therapeutics for $1.9bn

Diurnal Group - A new dawn

Basilea's lisavanbulin

Basilea reports further detail on derazantinib/checkpoint inhibitor combination

Basilea reports positive results for derazantinib in biliary cancer

Further good news from Basilea's Cresemba

Diurnal Group JCEM publication

Diurnal Group and Chronocort

Diurnal Business Update

Basilea preliminary 2020 revenue and portfolio progress